Potential Pfizer-Allergan merger brings corporate inversions back into the spotlight.

November 5, 2015

U.S. pharmaceutical company Pfizer Inc. and Irish Botox maker Allergan Plc have publicly indicated that they are engaged in “friendly” merger talks, reflecting Pfizer's second major attempt in as many years to shift its headquarters out of the U.S. in a so-called corporate inversion. Although IRS issued administrative guidance last year in efforts to make it more difficult for U.S. entities to invert and to reduce the tax benefits of doing so, this latest deal shows that at least some companies still find the end result worthwhile—and that any real crackdown may have to come from Congress.

   

Back to List

Client Center

Using Your Client Organizer
How to Review My 1040
Using File Exchange

Go Mobile!

...and get what you need, when and where you need it!

Articles

How to drive your business into the ground

Josh Nowack

January 7, 2017

From time to time, clients will ask me to check out investment opportunities.  And for avoidance of doubt, I do so not to recommend an investment and certainly not to sell investments....

Read More...

Phone: 949-354-5495 • Fax: 949-354-5486
Email: info@nowackcpa.com